Boyle, F., Okera, M., Sezgin Goksu, S., van Hal, G., Bellet Ezquerra, M., Loi, S., & Lim, E. (2022). An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
Citación estilo ChicagoBoyle, Frances, Meena Okera, Sema Sezgin Goksu, Gertjan van Hal, Meritxell Bellet Ezquerra, Sherene Loi, y Elgene Lim. An Open Label, Randomized Phase 2 Trial Assessing the Impact of Food On the Tolerability of Abemaciclib in Patients With Advanced Breast Cancer. 2022.
Cita MLABoyle, Frances, et al. An Open Label, Randomized Phase 2 Trial Assessing the Impact of Food On the Tolerability of Abemaciclib in Patients With Advanced Breast Cancer. 2022.
Precaución: Estas citas no son 100% exactas.